

Zanidatamab

Cat. No.:	HY-P99380
CAS No.:	2169946-15-8
Target:	EGFR
Pathway:	JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Zanidatamab (ZW25) is a humanised, bispecific monoclonal antibody targeting 2 distinct HER2 epitopes (ECD2 and ECD4). Zanidatamab has anti-tumour activity ^[1] .
IC ₅₀ & Target	HER2
In Vitro	<p>Zanidatamab (ZW25) has low nM binding affinity (0.9-16 nM) to recombinant HER2 and to cultured cancer cells with a range of HER2 expression^[1].</p> <p>Zanidatamab inhibits the growth of human cancer cell lines with a wide range of HER2 expression (5-54% inhibition depending on the cell line), and inhibits ligand-mediated tumor cell proliferation^[1].</p> <p>Zanidatamab elicits concentration-dependent ADCC at nM potency (0.05-64 nM) with maximal lysis up to 52% on TNBC cell lines expressing HER2 and exhibits synergy and additivity with multiple chemotherapeutic agents including platins, taxanes, microtubule inhibitors, and DNA synthesis inhibitors in various HER2 expressing tumor cell lines^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>
In Vivo	<p>Zanidatamab (ZW25) induces significant tumor regressions, exhibiting 307% tumor growth inhibition relative to hlgG control and a 70% complete regression rate^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>

REFERENCES

[1]. Weisser N, et, al. Preclinical development of a novel biparatopic HER2 antibody with activity in low to high HER2 expressing cancers. Cancer Res. 2017;77 (13).

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA